Neurotechnology
Synchron
Developer of the Stentrode, a brain-computer interface delivered through blood vessels without open-skull surgery, targeting patients with paralysis. Synchron raised a $200 million Series D in November 2025 (bringing total funding to $345 million) to fund a 2026 pivotal clinical trial -- the study required before Synchron can seek the first FDA premarket approval (PMA) for an implantable BCI -- and is developing a next-generation, higher-channel-count transcatheter interface at a new San Diego engineering hub.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources · 66% avg. source confidence
- MedTech Dive / Fierce Biotech — Synchron raises $200M Series D to fund 2026 pivotal BCI trial68% source confidence
- Tech Times — Synchron targets 2026 pivotal trial for first FDA-approved BCI64% source confidence
Dependency Map
What Synchron depends on below, and who depends on Synchron above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Synchron's Timeline
A sourced, dated history of Synchron's key moments — founding to present.
Jan 2012 · Founded
Synchron was founded to develop the Stentrode, a blood-vessel-delivered brain-computer interface avoiding open-skull surgery.
Nov 2025 · $200M Series D for 2026 pivotal trial
Synchron raised a $200 million Series D round to fund a 2026 pivotal clinical trial and prepare its first-generation device for commercial launch, bringing total funding to $345 million.